MedImmune to Develop Compugen Immuno-Oncology Antibodies

AstraZeneca’s MedImmune subsidiary has agreed to exclusively license and develop bispecific and multispecific immuno-oncology antibody products from Compugen’s pipeline, through a collaboration that Compugen said today could generate for it up to $210 million-plus.Compugen said it will grant MedImmune an exclusive license to develop bispecific and multispecific antibody products derived from a Compugen pipeline program.The pipeline program was not specified in a Compugen announcement